Immuneering

Immunotherapy clinical trials show promise for long-term survival in various cancers, with Aethlon Medical's Hemopurifier® designed to improve response rates to anti-PD-1 therapies by removing tumor-derived extracellular vesicles. Positive initial data from Immuneering Corporation's Phase 2a trial of IMM-1-104 in pancreatic cancer and Iovance Biotherapeutics' lifileucel in advanced melanoma further support the potential of immunotherapy.

Aethlon Medical's Hemopurifier®, an immunotherapeutic device for cancer, gains ethics approval in India for a trial in solid tumor patients resistant to anti-PD-1 therapy. The trial aims to assess safety and feasibility, with potential to improve response rates to anti-PD-1 antibodies by removing tumor-produced extracellular vesicles.

Solid tumors market projected to reach $375.4B by 2034 with 7.45% CAGR. Aethlon Medical activates Hemopurifier trial at Royal Adelaide Hospital for solid tumor patients resistant to anti-PD-1 therapies. Immuneering reports positive initial data for IMM-1-104 in pancreatic cancer. FDA approves new immunotherapy combinations for endometrial cancer from AstraZeneca, Merck, and GlaxoSmithKline. Roche's trastuzumab deruxtecan receives accelerated approval for HER2-positive solid tumors.

Initial Phase 2a trial results for IMM-1-104 combined with gemcitabine/nab-paclitaxel in pancreatic cancer show a 40% response rate and 80% disease control rate among the first five patients. IMM-1-104 is well-tolerated, with further dosing at 320 mg QD approved. Data aligns with preclinical findings, indicating potential for deeper responses than chemotherapy alone.